Research Topics
| K RossingSummaryAffiliation: University of Copenhagen Country: Denmark Publications
| Collaborators
|
Detail Information
Publications
Progression of nephropathy in type 2 diabetic patientsKasper Rossing
Department of Physiology, Steno Diabetes Center, Gentofte, Denmark
Kidney Int 66:1596-605. 2004....- Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trialKasper Rossing
Steno Diabetes Center, Gentofte, Denmark
Diabetes Care 26:2268-74. 2003.... - Impact of diabetic nephropathy and angiotensin II receptor blockade on urinary polypeptide patternsKasper Rossing
Steno Diabetes Center, Gentofte, Denmark
Kidney Int 68:193-205. 2005..New insights into the pathogenesis and treatment of diabetic renal disease may emerge from recent advances in proteomics using high-throughput mass spectrometry (MS) of urine... - Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuriaKasper Rossing
Steno Diabetes Center, Gentofte, Denmark
Kidney Int 68:1190-8. 2005..The purpose of this study was to evaluate the renoprotective effect as reflected by short-term changes in albuminuria of ultrahigh doses of irbesartan in type 2 diabetic patients with microalbuminuria... - Comparative effects of Irbesartan on ambulatory and office blood pressure: a substudy of ambulatory blood pressure from the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria studyKasper Rossing
Steno Diabetes Center, Niels Steensens Vej 2, 2820 Gentofte, Denmark
Diabetes Care 26:569-74. 2003..In the present study, we evaluated 24-h blood pressure patterns in a subpopulation of the IRMA2 trial... - Remission of nephrotic-range albuminuria reduces risk of end-stage renal disease and improves survival in type 2 diabetic patientsK Rossing
Steno Diabetes Center, Gentofte, Denmark
Diabetologia 48:2241-7. 2005..We evaluated the impact of remission of nephrotic-range albuminuria (>2500 mg/24 h) (NRA) on end-stage renal disease (ESRD) and mortality in type 2 diabetic patients with nephropathy... 
Urinary proteomics in diabetes and CKDKasper Rossing
Steno Diabetes Center, Niels Steensens Vej 2, DK 2820 Gentofte, Denmark
J Am Soc Nephrol 19:1283-90. 2008..In conclusion, this study shows that analysis of the urinary proteome may allow early detection of diabetic nephropathy and may provide prognostic information...- Pregnancy and progression of diabetic nephropathyK Rossing
Steno Diabetes Center, Niels Steensens Vej 2, DK 2820 Gentofte, Denmark
Diabetologia 45:36-41. 2002..Pregnancy could damage kidney function in diabetic nephropathy. We investigated the long-term impact of pregnancy on the progression of diabetic nephropathy... - Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover studyKasper Rossing
Steno Diabetes Center, Gentofte, Denmark
Diabetes Care 25:95-100. 2002..g., lisinopril/enalapril at 20 mg daily. We tested the concept that such patients might benefit from dual blockade of the renin-angiotensin system (RAS)... 
Optimal dose of lisinopril for renoprotection in type 1 diabetic patients with diabetic nephropathy: a randomised crossover trialK J Schjoedt
Steno Diabetes Center, Gentofte, Denmark
Diabetologia 52:46-9. 2009....- Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathyK J Schjoedt
Steno Diabetes Center, Gentofte, Denmark
Kidney Int 70:536-42. 2006.... - Evolving strategies for renoprotection: diabetic nephropathyH H Parving
Steno Diabetes Center, Copenhagen, Denmark
Curr Opin Nephrol Hypertens 10:515-22. 2001..Many potential treatment modalities in preventing and treating diabetic nephropathy are presently being evaluated... - Dual blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy: the role of aldosteroneK J Schjoedt
Steno Diabetes Center, Niels Steensens Vej 2, 2820 Gentofte, Denmark
Horm Metab Res 37:4-8. 2005..The beneficial response may be influenced by genetic factors and reductions in blood pressure and plasma aldosterone concentrations... - Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over studyKasper Rossing
Steno Diabetes Center, Niels Steensens Vej 2, DK 2820 Gentofte, Denmark
Diabetes Care 28:2106-12. 2005.... - Optimal dose of candesartan for renoprotection in type 2 diabetic patients with nephropathy: a double-blind randomized cross-over studyKasper Rossing
Steno Diabetes Center, Gentofte, Denmark. Faculty of Health Science, University of Aarhus, Aarhus, Denmark
Diabetes Care 26:150-5. 2003..05 versus placebo). CONCLUSIONS: The optimal dose of candesartan is 16 mg daily for renoprotection, as reflected by short-term reduction in albuminuria, in hypertensive type 2 diabetic patients with nephropathy... - Effect of short-term hyperglycaemia on haemodynamics in type 1 diabetic patientsP Jacobsen
Steno Diabetes Center, Gentofte, Denmark
J Intern Med 254:464-71. 2003..We tested the impact of short-term hyperglycaemia on systemic blood pressure and regulatory hormones in type 1 diabetic patients... - Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end pointsHans Henrik Parving
Steno Diabetes Center, Copenhagen, Denmark
Semin Nephrol 24:147-57. 2004..The studies mentioned here suggest that ARB represents a beneficial treatment of hypertension and proteinuria in incipient and overt diabetic nephropathy... - Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathyPeter Jacobsen
Steno Diabetes Center, Gentofte, Denmark
Nephrol Dial Transplant 17:1019-24. 2002..We tested the effect of dual blockade of the renin-angiotensin system (RAS) in these patients... - Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathyPeter Jacobsen
Steno Diabetes Center, Gentofte, Denmark
Curr Opin Nephrol Hypertens 13:319-24. 2004.... - Monitoring kidney function in type 2 diabetic patients with incipient and overt diabetic nephropathyPeter Rossing
Steno Diabetes Center, Gentofte, Denmark
Diabetes Care 29:1024-30. 2006.... - Beneficial impact of spironolactone in diabetic nephropathyKatrine Jordan Schjoedt
Steno Diabetes Center, Gentofte, Denmark
Kidney Int 68:2829-36. 2005..We therefore aimed to evaluate the short-term effect of aldosterone antagonism with spironolactone on albuminuria and blood pressure in diabetic nephropathy... - Decreasing incidence of severe diabetic microangiopathy in type 1 diabetesPeter Hovind
Steno Diabetes Center, Gentofte, Denmark
Diabetes Care 26:1258-64. 2003..To assess recent trends in the cumulative incidence of diabetic microangiopathy in type 1 diabetes, we analyzed data from long-term prospective observational studies lasting >/=20 years... - Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathyPeter Jacobsen
Steno Diabetes Center, Gentofte, Denmark
Kidney Int 63:1874-80. 2003.... - Reduction of urinary connective tissue growth factor by Losartan in type 1 patients with diabetic nephropathySteen Andersen
Steno Diabetes Center, Gentofte, Denmark
Kidney Int 67:2325-9. 2005..The present study aimed to investigate the short- and long term effects of angiotensin II receptor blockade by Losartan on urinary CTGF levels in hypertensive type 1 diabetic patients with diabetic nephropathy... - Progression and remission of nephropathy in type 2 diabetes: new strategies of treatment and monitoringKasper Rossing
Steno Diabetes Centre, Gentofte
Dan Med Bull 54:79-98. 2007